Company Filing History:
Years Active: 1999-2000
Title: Janet Tseng-Law: Innovator in Cell Selection Technologies
Introduction
Janet Tseng-Law is a prominent inventor based in Whittier, CA (US). She has made significant contributions to the field of cell selection technologies, holding 2 patents that focus on innovative methods for the release and selection of specific cell types.
Latest Patents
Her latest patents include groundbreaking inventions related to positive and positive/negative cell selection mediated by peptide release. These inventions provide non-enzymatic methods for the release of cells that have been selected from heterogeneous cell suspensions through antibody-mediated binding to solid supports. The methods involve forming a complex within the cell suspension that includes a solid support linked to a primary monoclonal antibody, which is bound to a cell surface antigen on the target cells. By contacting this complex with a specific peptide, the primary antibody is displaced from the cell surface antigen, allowing for the release of the target cell. This technology is particularly useful for the positive selection of CD34+ hematopoietic stem cells, which can be reinfused into cancer patients after high-dose therapy to help reconstitute their immune systems.
Career Highlights
Janet Tseng-Law is currently associated with Nexell Therapeutics Inc., where she continues to advance her research and innovations in cell selection technologies. Her work has the potential to significantly impact cancer treatment and regenerative medicine.
Collaborations
She collaborates with notable colleagues, including Joan A Kobori and Fahad A Al-Abdaly, contributing to a dynamic research environment that fosters innovation.
Conclusion
Janet Tseng-Law's contributions to cell selection technologies exemplify her commitment to advancing medical science. Her innovative patents and ongoing work at Nexell Therapeutics Inc. position her as a key figure in the field.